Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. 2000

S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
Department of Dermatology, Kanazawa University School of Medicine, Kanazawa, Japan. s-sato@med.kanazawa-u.ac.jp

BACKGROUND Serum KL-6 has been suggested to be a useful marker for the evaluation of interstitial lung disease activity. OBJECTIVE To determine the correlation between serum KL-6 levels and pulmonary fibrosis in patients with systemic sclerosis (SSc). METHODS Serum samples from patients with limited cutaneous SSc (lSSc; n = 19), diffuse cutaneous SSc (dSSc; n = 26) and normal individuals (n = 15) were examined by ELISA. RESULTS Serum KL-6 levels in SSc patients were significantly higher than those in normal controls. KL-6 levels in dSSc patients were significantly elevated compared with those in lSSc patients. Elevated KL-6 levels were associated with the presence of pulmonary fibrosis in SSc patients or dSSc patients. Furthermore, KL-6 levels inversely correlated with percentages of diffusion capacity of carbon monoxide and vital capacity in SSc patients or dSSc patients. CONCLUSIONS KL-6 may be a simple, serologic indicator for the severity of pulmonary fibrosis in SSc.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009077 Mucins High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface. Mucin
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
January 2003, Clinical and experimental rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
April 2000, The Journal of rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
April 1997, The Journal of rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
January 2014, Clinical and experimental rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
June 2011, Clinical rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
October 2011, The Journal of rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
August 2009, The Journal of rheumatology,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
June 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
September 2018, The clinical respiratory journal,
S Sato, and T Nagaoka, and M Hasegawa, and C Nishijima, and K Takehara
January 2009, The Journal of rheumatology,
Copied contents to your clipboard!